These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 23617883)

  • 1. Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma.
    Katanasaka Y; Kodera Y; Kitamura Y; Morimoto T; Tamura T; Koizumi F
    Mol Cancer; 2013 Apr; 12():31. PubMed ID: 23617883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway.
    Bonavia R; Inda MM; Vandenberg S; Cheng SY; Nagane M; Hadwiger P; Tan P; Sah DW; Cavenee WK; Furnari FB
    Oncogene; 2012 Sep; 31(36):4054-66. PubMed ID: 22139077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.
    Yiin JJ; Hu B; Schornack PA; Sengar RS; Liu KW; Feng H; Lieberman FS; Chiou SH; Sarkaria JN; Wiener EC; Ma HI; Cheng SY
    Mol Cancer Ther; 2010 Apr; 9(4):929-41. PubMed ID: 20371720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
    Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
    Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ANGPTL4 Induces TMZ Resistance of Glioblastoma by Promoting Cancer Stemness Enrichment via the EGFR/AKT/4E-BP1 Cascade.
    Tsai YT; Wu AC; Yang WB; Kao TJ; Chuang JY; Chang WC; Hsu TI
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.
    Liu Z; Han L; Dong Y; Tan Y; Li Y; Zhao M; Xie H; Ju H; Wang H; Zhao Y; Zheng Q; Wang Q; Su J; Fang C; Fu S; Jiang T; Liu J; Li X; Kang C; Ren H
    Oncotarget; 2016 Jan; 7(4):4680-94. PubMed ID: 26717039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C/EBPβ promotes angiogenesis through secretion of IL-6, which is inhibited by genistein, in EGFRvIII-positive glioblastoma.
    Liu X; Liu K; Qin J; Hao L; Li X; Liu Y; Zhang X; Liu X; Li P; Han S; Mao Z; Shen L
    Int J Cancer; 2015 Jun; 136(11):2524-34. PubMed ID: 25382637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSMB8 inhibition decreases tumor angiogenesis in glioblastoma through vascular endothelial growth factor A reduction.
    Chang HH; Cheng YC; Tsai WC; Chen Y
    Cancer Sci; 2020 Nov; 111(11):4142-4153. PubMed ID: 32816328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non-coding RNA LPP-AS2 promotes glioma tumorigenesis via miR-7-5p/EGFR/PI3K/AKT/c-MYC feedback loop.
    Zhang X; Niu W; Mu M; Hu S; Niu C
    J Exp Clin Cancer Res; 2020 Sep; 39(1):196. PubMed ID: 32962742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
    Hu J; Jo M; Cavenee WK; Furnari F; VandenBerg SR; Gonias SL
    Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15984-9. PubMed ID: 21896743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
    Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR/c-myc axis regulates TGFβ/Hippo/Notch pathway via epigenetic silencing miR-524 in gliomas.
    Zhao K; Wang Q; Wang Y; Huang K; Yang C; Li Y; Yi K; Kang C
    Cancer Lett; 2017 Oct; 406():12-21. PubMed ID: 28778566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.
    Chou ST; Patil R; Galstyan A; Gangalum PR; Cavenee WK; Furnari FB; Ljubimov VA; Chesnokova A; Kramerov AA; Ding H; Falahatian V; Mashouf L; Fox I; Black KL; Holler E; Ljubimov AV; Ljubimova JY
    J Control Release; 2016 Dec; 244(Pt A):14-23. PubMed ID: 27825958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
    Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
    Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
    Eskilsson E; Rosland GV; Talasila KM; Knappskog S; Keunen O; Sottoriva A; Foerster S; Solecki G; Taxt T; Jirik R; Fritah S; Harter PN; Välk K; Al Hossain J; Joseph JV; Jahedi R; Saed HS; Piccirillo SG; Spiteri I; Leiss L; Euskirchen P; Graziani G; Daubon T; Lund-Johansen M; Enger PØ; Winkler F; Ritter CA; Niclou SP; Watts C; Bjerkvig R; Miletic H
    Neuro Oncol; 2016 Dec; 18(12):1644-1655. PubMed ID: 27286795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels.
    Ding C; Luo J; Fan X; Li L; Li S; Wen K; Feng J; Wu G
    J Exp Clin Cancer Res; 2017 Apr; 36(1):56. PubMed ID: 28420432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The inhibitor of growth 1 (ING1) proteins suppress angiogenesis and differentially regulate angiopoietin expression in glioblastoma cells.
    Tallen G; Farhangi S; Tamannai M; Holtkamp N; Mangoldt D; Shah S; Suzuki K; Truss M; Henze G; Riabowol K; von Deimling A
    Oncol Res; 2009; 18(2-3):95-105. PubMed ID: 20066899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioblastoma Cell Resistance to EGFR and MET Inhibition Can Be Overcome via Blockade of FGFR-SPRY2 Bypass Signaling.
    Day EK; Sosale NG; Xiao A; Zhong Q; Purow B; Lazzara MJ
    Cell Rep; 2020 Mar; 30(10):3383-3396.e7. PubMed ID: 32160544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
    Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.